VTGNVistaGen Therapeutics Inc
$0.235
$0.0039
(1.69%)
Closed $0.235
$0.0021
(0.89%)
After Hours
EarningsAug 6
Mkt Cap$9.48M
Vol555,469.00
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of...
Business Wire
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2026...
Business Wire
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Companys clinical program for fasedienol nasal spray...
Business Wire
Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates
Veeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, June 1, 2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates
HealthEquity (HQY) delivered earnings and revenue surprises of +11.57% and +0.06%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare...
Business Wire
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Latest VTGN News
ViewThis Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell
Stocktwits
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business Wire
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Business Wire
Advertisement|Remove ads.